ArticleDrug delivery2018
Gastroretentive raft liquid delivery system as a new approach to release extension for carrier-mediated drug.
Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 54 citations in OpenAlex.
- Current Developments in the Delivery of Gastro-Retentive Drugs.AAPS PharmSciTech · 2025Review
- Maximizing the Use of Ivermectin Transethosomal Cream in the Treatment of Scabies.Pharmaceutics · 2024Article
- In Vitro and In Vivo Evaluation of Magnetic Floating Dosage Form by Alternating Current Biosusceptometry.Pharmaceutics · 2024Article
- Enhanced gastric residence time of acyclovir by floating raft formulation using box-behnken design.Heliyon · 2024Article
- Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine.Drug delivery · 2023Article
- Determination of Mucoadhesion of Polyvinyl Alcohol Films to Human Intestinal Tissue.Pharmaceutics · 2023Article
- The development of an in-situ biopolymer-based floating gel for the oral delivery of metformin hydrochloride.Heliyon · 2023Article
- Investigation of Alogliptin-Loaded In Situ Gel Implants by 2Pharmaceutics · 2022Article
- Tailoring thixotropic mixed-lipid nanoconstructs of voriconazole for the management of Vulvovaginal candidiasis: Formulation, statistical optimization,Drug delivery · 2021Article
- Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications.Pharmaceutics · 2021Review
- In-Depth Study into Polymeric Materials in Low-Density Gastroretentive Formulations.Pharmaceutics · 2020Review
- In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms.Pharmaceutics · 2019Review
- Mechanically Robust Gastroretentive Drug-Delivery Systems Capable of Controlling Dissolution Behaviors of Coground β-Lapachone.Pharmaceutics · 2019Article
- Current State and Future Perspectives on Gastroretentive Drug Delivery Systems.Pharmaceutics · 2019Review
- Improved gastric residence time of famotidine by raft-forming drug delivery system using DOE.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gabapentin (GBP), an antiepileptic and anti-neuropathic agent, suffers from short half-life (5-7 h), has narrow absorption window, and is absorbed via carrier-mediated mechanism resulting in frequent dosing, poor compliance, and poor bioavailability (<60%). Moreover, GBP is a freely water-soluble drug, thus it is considered a challenging candidate to be formulated as extended release dosage form. In this study, raft forming systems were investigated as a potential drug delivery system for prolonging gastric residence time of GBP. A 2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.